Prime Medicine Inc. (PRME)
Prime Medicine Statistics
Share Statistics
Prime Medicine has 131.16M shares outstanding. The number of shares has increased by 9.27% in one year.
| Shares Outstanding | 131.16M |
| Shares Change (YoY) | 9.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 53.98% |
| Shares Floating | 51.92M |
| Failed to Deliver (FTD) Shares | 32.87K |
| FTD / Avg. Volume | 2.65% |
Short Selling Information
The latest short interest is 17.21M, so 13.12% of the outstanding shares have been sold short.
| Short Interest | 17.21M |
| Short % of Shares Out | 13.12% |
| Short % of Float | 33.82% |
| Short Ratio (days to cover) | 15.18 |
Valuation Ratios
The PE ratio is -1.77 and the forward PE ratio is -2.3. Prime Medicine's PEG ratio is 0.07.
| PE Ratio | -1.77 |
| Forward PE | -2.3 |
| PS Ratio | 116.1 |
| Forward PS | 3.2 |
| PB Ratio | 2.26 |
| P/FCF Ratio | -2.66 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Prime Medicine.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.27.
| Current Ratio | 5.58 |
| Quick Ratio | 5.58 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.31 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $13.94K |
| Profits Per Employee | $-915.34K |
| Employee Count | 214 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.78% in the last 52 weeks. The beta is 1.89, so Prime Medicine's price volatility has been higher than the market average.
| Beta | 1.89 |
| 52-Week Price Change | -78.78% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 3.56 |
| Relative Strength Index (RSI) | 27.5 |
| Average Volume (20 Days) | 1.24M |
Income Statement
In the last 12 months, Prime Medicine had revenue of 2.98M and earned -195.88M in profits. Earnings per share was -1.65.
| Revenue | 2.98M |
| Gross Profit | 2.98M |
| Operating Income | -202.47M |
| Net Income | -195.88M |
| EBITDA | -202.47M |
| EBIT | -202.47M |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has 182.48M in cash and 40.79M in debt, giving a net cash position of 141.68M.
| Cash & Cash Equivalents | 182.48M |
| Total Debt | 40.79M |
| Net Cash | 141.68M |
| Retained Earnings | -687.21M |
| Total Assets | 297.51M |
| Working Capital | 173.93M |
Cash Flow
In the last 12 months, operating cash flow was -122.86M and capital expenditures -7.29M, giving a free cash flow of -130.16M.
| Operating Cash Flow | -122.86M |
| Capital Expenditures | -7.29M |
| Free Cash Flow | -130.16M |
| FCF Per Share | -1.1 |
Margins
Gross margin is 100%, with operating and profit margins of -6787.36% and -6566.61%.
| Gross Margin | 100% |
| Operating Margin | -6787.36% |
| Pretax Margin | -6566.61% |
| Profit Margin | -6566.61% |
| EBITDA Margin | -6787.36% |
| EBIT Margin | -6787.36% |
| FCF Margin | -4363.36% |
Dividends & Yields
PRME does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PRME is $12, which is 860% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 860% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -3.93 |
| Piotroski F-Score | 5 |